Salix Pharmaceuticals Ltd (SLXP) Tops Q3 EPS by 14c
Tweet
Share
E-mailGet Alerts SLXP Hot Sheet
Join SI Premium – FREE
Salix Pharmaceuticals Ltd (NASDAQ: SLXP) reported Q3 EPS of $0.77, $0.14 better than the analyst estimate of $0.63. Revenue for the quarter came in at $146.2 million versus the consensus estimate of $140.56 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Blackhawk Network (HAWK) Reports Q2 Loss of $0.07; Offers Guidance
- Marpai, Inc. (MRAI) Misses Q2 EPS by 18c
- Acurx Pharmaceuticals (ACXP) Tops Q2 EPS by 4c
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
